Hematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Clin Lab Anal. 2021 Apr;35(4):e23725. doi: 10.1002/jcla.23725. Epub 2021 Mar 5.
Hematopoietic cancers are among the most common malignancies worldwide, which are divided into different types depending on the origin of tumor cells. In recent years, the pivotal role of different signaling pathways in the onset and progression of these cancer types has been well established. One of these pathways, whose role in blood malignancies has been well-defined, is PI3K/mTOR/AKT axis. The signaling pathway involves in a wide variety of important biological events in cells. It is clear that dysregulation of mediators involved in PI3 kinase signaling takes a pivotal role in cancer development. Considering the undeniable role of miRNAs, as one of the well-known families of non-coding RNAs, in gene regulation, we aimed to review the role of miRNAs in regulation of PI3 kinase signaling effectors in hematopoietic cancers.
造血系统恶性肿瘤是全球最常见的恶性肿瘤之一,根据肿瘤细胞起源的不同,可分为不同类型。近年来,不同信号通路在这些癌症类型的发生和进展中的关键作用已得到充分证实。其中一个通路,即 PI3K/mTOR/AKT 轴,其在血液恶性肿瘤中的作用已得到充分定义。该信号通路涉及细胞内的多种重要生物学事件。很明显,参与 PI3 激酶信号的介质失调在癌症的发生中起着关键作用。鉴于 miRNA 作为已知的非编码 RNA 家族之一,在基因调控中具有不可否认的作用,我们旨在综述 miRNA 在调节造血系统恶性肿瘤中 PI3 激酶信号效应物中的作用。